Thoratec Continues Push For Class IIIB Patient Inclusion In LVAD Coverage
This article was originally published in The Gray Sheet
Executive Summary
Thoratec is continuing to advocate for left ventricular assist device destination therapy Medicare coverage expansion that includes New York Heart Association Class IIIB patients, though the firm acknowledges CMS is unlikely to alter its proposed coverage expansion limited to Class IV patients
You may also be interested in...
CMS Proposes Limited LVAD Destination Therapy Coverage Expansion
Medicare coverage for left ventricular assist devices as destination therapy would gain a limited expansion under an Aug. 19 CMS proposed national coverage decision
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.